Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain

Pain

Volumn 135, Issue 3, 2008, Pages 217-220

  McQuay, Henry J ^a   Derry, Sheena ^a   Moore, R Andrew ^a   Poulain, Philippe ^b   Legout, Valérie ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CLONIDINE; FENTANYL; GABAPENTIN; LIDOCAINE; OXYMORPHONE; PLACEBO; PREGABALIN; TRAMADOL;

CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; LOW BACK PAIN; META ANALYSIS; MIGRAINE; NEUROPATHIC PAIN; NOCICEPTION; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALGESICS; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; HUMANS; PAIN, INTRACTABLE; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 40049083562     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.01.014     Document Type: Review

References (14)

1. Dahlof C.G., Pascual J., Dodick D.W., and Dowson A.J. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 26 (2006) 400-408
2. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., and Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 (2005) 289-305
3. Freidlin B., and Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 23 (2005) 5094-5098
4. Fries S., Grosser T., Price T.S., Lawson J.A., Kapoor S., DeMarco S., et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (2006) 55-64
5. Goadsby P.J., Massiou H., Pascual J., Diener H.C., Dahlof C.G., Mateos V., et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 115 (2007) 34-40
6. Klepstad P., Dale O., Skorpen F., Borchgrevink P.C., and Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49 (2005) 902-908
7. Kongsgaard U.E., and Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 2 (1998) 53-62
8. Kroenke K., West S.L., Swindle R., Gilsenan A., Eckert G.J., Dolor R., et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286 (2001) 2947-2955
9. Lee J.K., Grace K.A., and Taylor A.J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 296 (2006) 2563-2571
10. Lötsch J., and Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 121 (2006) 1-5
11. Moore R.A., Edwards J.E., and McQuay H.J. Acute pain: Individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 116 (2005) 322-331
12. Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M et al. Efficacy and safety of transdermal buprenorphine: a randomized-placebo-controlled trial in 289 patients with severe cancer pain. J Pain Sympt Manag, in press.
13. Senn S. Individual response to treatment: is it a valid assumption?. BMJ 329 (2004) 966-968
14. Simon G. Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA 286 (2001) 3003-3004